Rosuvastatin Efficacy and Safety for Cirrhosis in the United States (RESCU): A Double-Blind Randomized, Placebo-Controlled Phase 2 Study

Clinical Trial Details

This study is being conducted to evaluate if Rosuvastatin is safe and can help people living with cirrhosis lead longer, healthier lives.

This study drug has been approved by the U.S. Food and Drug Administration (FDA) to treat individuals with high cholesterol but has not been approved to treat cirrhosis so it is considered investigational/experimental in this study. An investigational/experimental drug is one that is currently being tested and has not been approved by FDA for sale in the United States or by any regulatory authorities in any country in the world. Experimental drugs such as rosuvastatin may be tested in research studies such as this one.

The study drug (rosuvastatin) will be given in the form of tablets. Participants will take 1 tablet by mouth once a day for 4 weeks.

Participation in this study will last approximately 2 years (24 months). Participants will be compensated for their time.

Key Eligibility:

Men and women who are 18 years and older.
Have been diagnosed with cirrhosis.

Detailed eligibility reviewed when you contact the study team.

Return to List

Study contact by location

Upper East Side - Manhattan

Contact(s)

646‐962‐4040
GIHepResearch@med.cornell.edu

Primary Investigator(s)

Robert S. Brown, MD, MPH

Protocol ID(s)

Weill Cornell Medicine IRB #:

2306026194

ClinicalTrials.gov:

NCT05832229

Status

Open to Enrollment

Age Group

Adult

Disease

Cirrhosis